Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 9/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 9/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | NNMT | P40261 | 9/20 | 0.34 |
| ▸ | AHCY | P23526 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28485444 | 1.00 | PRMT5 (0.36) | PRMT5WDR77FGFR1FGFR4NNMT | |
| SCHEMBL24067667 | 1.00 | PRMT5 (0.36) | PRMT5WDR77FGFR1FGFR4NNMT | |
| SCHEMBL29611802 | 1.00 | PRMT5 (0.36) | PRMT5WDR77FGFR1FGFR4NNMT | |
| SCHEMBL28619887 | 1.00 | PRMT5 (0.36) | PRMT5WDR77FGFR1FGFR4NNMT | |
| SCHEMBL9285043 | 0.89 | PRMT5 (0.36) | PRMT5WDR77NNMT | |
| SCHEMBL28636985 | 0.89 | PRMT5 (0.36) | PRMT5WDR77NNMT | |
| SCHEMBL30003589 | 0.89 | PRMT5 (0.36) | PRMT5WDR77NNMT | |
| SCHEMBL28621691 | 0.87 | PRMT5 (0.45) | PRMT5WDR77AHCY | |
| SCHEMBL18571514 | 0.87 | PRMT5 (0.45) | PRMT5WDR77AHCY | |
| SCHEMBL21090211 | 0.87 | NNMT (0.36) | PRMT5WDR77NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240051985-A1 | METTL3 MODULATORS | ACCENT THERAPEUTICS INC (US) | 2024-02-15 | — | — | US | disclosed |
| EP-3585904-B1 | USE OF BIOMARKERS IN IDENTIFYING CANCER PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-29 | — | — | EP | disclosed |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-19 | — | — | US | disclosed |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-19 | — | — | US | disclosed |
| EP-4229067-A1 | METTL3 MODULATORS | Accent Therapeutics, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4219496-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| US-20220218732-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2022-07-14 | — | — | US | disclosed |
| US-20220218732-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2022-07-14 | — | — | US | disclosed |
| US-20220205026-A1 | Use of Biomarkers in Identifying Cancer Patients That Will Be Responsive to Treatment With a PRMT5 Inhibitor | JANSSEN PHARMACEUTICA NV (BE) | 2022-06-30 | — | — | US | disclosed |
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
| WO-2018152548-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2018-08-23 | — | — | WO | disclosed |
| WO-2018065365-A1 | NOVEL MONOCYCLIC AND BICYCLIC RING SYSTEM SUBSTITUTED CARBANUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-12 | — | — | WO | disclosed |
| WO-2017153186-A1 | SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017032840-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | WO | disclosed |
| US-9458165-B2 | DOT1L inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458165-B2 | DOT1L inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458165-B2 | DOT1L inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160060269-A1 | DOT1L Inhibitors | DANA-FARBER CANCER INSTITUTE, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160060269-A1 | DOT1L Inhibitors | DANA-FARBER CANCER INSTITUTE, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160060269-A1 | DOT1L Inhibitors | DANA-FARBER CANCER INSTITUTE, INC. | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | PRMT5 1/4885WDR77 106/4885FGFR1 3459/4885 |
| US-20240051985-A1 | METTL3 MODULATORS | METTL3, METTL16, METTL14 | PRMT5 78/4885WDR77 119/4885FGFR1 2785/4885 |
| US-20160060269-A1 | DOT1L Inhibitors | DOT1L, MAP1LC3B, MAP1LC3A | PRMT5 608/4885WDR77 95/4885FGFR1 3932/4885 |
| US-20220218732-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRMT5, PRMT6, PRMT1 | PRMT5 1/4885WDR77 52/4885FGFR1 4128/4885 |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | PRMT5 1/4885WDR77 67/4885FGFR1 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.